Following a downgrade from Oppenheimer analyst Christopher Marai, Raptor Pharmaceutical Corp. (NASDAQ:RPTP)'s stock fell by more than 12% on Monday. However, shares have started to kick back and had...... (read more)

In the 21st century investor’s toolkit, there are dozens of indicators shareholders can use to analyze publicly traded companies. Some of the most innovative are hedge fund and insider trading activity...... (read more)

Biotechnology stocks often trade with excessive valuations, until one day, large losses occur. The best way to protect yourself is to be logical when investing, and use industrywide valuing metrics as...... (read more)

Orphan drug status, which is given to drugs meant for the treatment of rare diseases, offers drug developers a path to faster approval and enhanced market exclusivity. So let's look at a small early development...... (read more)

For years, satirical late-night TV host Stephen Colbert has been running a series on his show called "Better Know a District," which highlights one of the 435 U.S. congressional districts and its representative...... (read more)

In most cases, a biopharmaceutical company chooses to develop either high-priced orphan-designated drugs, or therapeutics to treat large patient populations. Yet one company in particular, Regeneron...... (read more)

Moreover, these Orphan designations are mostly awarded on drugs that treat small populations, but sometimes, these drugs can create massive amounts of revenue, and large valuations are given to the developing...... (read more)

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) signed an agreement with HealthCare Royalty Partners. On the face, this deal looks good for shareholders injecting much needed capital into the company. However...... (read more)

Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) was in 16 hedge funds' portfolio at the end of March. ASTX investors should be aware of an increase in hedge fund interest in recent months. There were 9 hedge...... (read more)

With the SPDR S&P Biotech Index up 31% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look...... (read more)